Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q3 2026 › vs Q3 2025
Biocryst Pharmaceuticals (BCRX) Q3 2026 vs Q3 2025 (year over year)
Biocryst Pharmaceuticals's revenue rose $20.9M (+13%) from $159M in Q3 2025 to $180M in Q3 2026. The biggest changes: Product +$14.6M (+9%); License and other revenues +$6.3M (+382%). Operating margin 29.6% against 18.6% (+11.0 pts).
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 29.6% | 18.6% | +11.0 pts |
| Net margin | 21.0% | 8.1% | +12.9 pts |
| Free cash flow margin | 18.2% | 25.3% | -7.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product | $172M | $158M | $14.6M | +9% |
| License and other revenues | $8.0M | $1.7M | $6.3M | +382% |
| Revenue | $180M | $159M | $20.9M | +13% |
| Operating profit | $53.3M | $29.6M | $23.7M | +80% |
| Costs & expenses | $127M | $130M | −$2.8M | -2% |
| Pre-tax earnings | $38.6M | $12.1M | $26.5M | +218% |
| Other expense, net | $14.7M | $17.5M | −$2.7M | -16% |
| Cost of revenue | $1.6M | $2.2M | −$613K | -28% |
| Research & development | $58.2M | $44.6M | $13.6M | +31% |
| SG&A | $67.2M | $83.0M | −$15.8M | -19% |
| Net earnings | $37.9M | $12.9M | $25.0M | +194% |
| Income tax | $669K | −$769K | $1.4M | — |
| Depreciation & amortization | $244K | $335K | −$91K | -27% |
| Share-based compensation | $14.2M | $18.6M | −$4.4M | -23% |
| Working capital & other | $19.4M | −$9.8M | $29.2M | — |
| Operating cash flow | $33.0M | $41.6M | −$8.6M | -21% |
| Free cash flow (OCF − capex) | $32.8M | $40.3M | −$7.5M | -19% |
| Capital expenditures | $233K | $1.3M | −$1.1M | -83% |
Questions
How much did Biocryst Pharmaceuticals's revenue grow year over year in Q3 2026?
Biocryst Pharmaceuticals's revenue rose $20.9M (+13%) from $159M in Q3 2025 to $180M in Q3 2026.
What drove Biocryst Pharmaceuticals's revenue change in Q3 2026?
Product +$14.6M (+9%); License and other revenues +$6.3M (+382%).